替妥木单抗相关高血糖:大规模跨国队列研究
该回顾性队列研究基于TriNetX全球协作网络,经倾向评分匹配后比较792例接受替妥木单抗治疗的甲状腺眼病患者与792例对照。结果显示替妥木单抗与5年糖尿病前期(HR 2.03,CI 1.51-2.72)、糖尿病(HR 2.23,CI 1.46-3.43)及加用降糖药(HR 1.68,CI 1.27-2.22)风险显著增加相关,但绝对风险增幅不大。
要点
- 替妥木单抗治疗与5年糖尿病前期风险显著增加相关(HR 2.03)。
- 替妥木单抗治疗与5年新发糖尿病风险显著增加相关(HR 2.23)。
- 建议治疗期间常规监测血糖并积极管理血糖。
核心结论
- 替妥木单抗治疗与血糖异常风险增加相关,但绝对风险增幅不大。
- 研究支持对接受替妥木单抗治疗的甲状腺眼病患者进行常规血糖监测和积极血糖管理。
研究设计与样本
- 回顾性队列研究,使用TriNetX全球协作网络(超过165个医疗组织)数据。
- 经倾向评分匹配后,792例替妥木单抗治疗的甲状腺眼病患者与792例未接受该治疗的对照进行比较。
- 随访时间6个月至5年,采用Kaplan-Meier生存曲线进行时间-事件分析。
主要发现
- 5年糖尿病前期风险:替妥木单抗组HR 2.03(CI 1.51-2.72),发生率为24%,对照组为10%。
- 5年新发糖尿病风险:替妥木单抗组HR 2.23(CI 1.46-3.43)。
- 5年需加用降糖药风险:替妥木单抗组HR 1.68(CI 1.27-2.22)。
关键数值与推荐
- 主要结局包括新发糖尿病前期、糖尿病、随机血糖≥200 mg/dL定义的高血糖及随访期间启动降糖药物治疗。
临床怎么用
- 对接受替妥木单抗治疗的甲状腺眼病患者应常规监测血糖。
- 治疗期间发现血糖异常应积极管理。
- 考虑替妥木单抗治疗时需个体化评估风险获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Teprotumumab, a monoclonal antibody targeting the insulin-like growth factor-1 receptor, represents the first Food and Drug Administration (FDA)-approved treatment for thyroid eye disease (TED). However, hyperglycemia has emerged as a significant adverse event, with limited real-world data on its incidence and clinical impact. This study aimed to evaluate the risk of glycemic abnormalities associated with teprotumumab treatment using a large, multinational electronic health records database. METHODS: We conducted a retrospective cohort study using the TriNetX Global Collaborative Network, which includes data from more than 165 health care organizations worldwide. Patients with TED treated with teprotumumab were matched 11 to TED patients who did not receive teprotumumab using propensity score matching (PSM). The primary outcomes were incident prediabetes, diabetes, hyperglycemia defined by a random blood glucose level ≥200 mg/dL, and initiation of antidiabetes medications during follow-up ranging from 6 months to 5 years. Time-to-event analyses were performed using Kaplan-Meier survival curves to estimate cumulative incidence over time. RESULTS: After PSM, 792 teprotumumab-treated patients were compared with 792 matched controls over a follow-up period of up to 5 years. Teprotumumab treatment was associated with a significantly increased risk of prediabetes at 5 years (HR: 2.03, CI: 1.51-2.72), affecting 24% of treated patients compared with 10% of controls. The risk of incident diabetes at 5 years was also significantly higher in the teprotumumab-treated patients (HR: 2.23, CI: 1.46-3.43). Teprotumumab-treated patients were more likely to require the addition of antidiabetes medications at 5 years (HR: 1.68, CI: 1.27-2.22). CONCLUSIONS: In this large-scale cohort study, teprotumumab treatment was associated with an increased risk of dysglycemia. Although this risk was observed across several glycemic outcomes, the absolute risk increase was modest. These findings support routine glucose monitoring and proactive glycemic management, while emphasizing the importance of individualized risk-benefit assessment when considering teprotumumab therapy in patients with TED.
引用
- Lishinsky-Fischer N, Pollack R, Gur Z, et al. Teprotumumab-Associated Hyperglycemia: A Large-Scale Multinational Cohort Study. Thyroid. 2026. PMID: 41954033. doi:10.1177/10507256261442501
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。